Iptakalim Hydrochloride

CAS No. 642407-63-4

Iptakalim Hydrochloride( —— )

Catalog No. M27888 CAS No. 642407-63-4

Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 56 In Stock
5MG 46 In Stock
10MG 70 In Stock
25MG 141 In Stock
50MG 224 In Stock
100MG 338 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Iptakalim Hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist.
  • Description
    Iptakalim, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (KATP) opener, as well as an α4β2-containing nicotinic acetylcholine receptor (nAChR) antagonist. Iptakalim is also a K(ir) 6.1/SUR2B activator that can attenuate hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.
  • In Vitro
    Iptakalim (Ipt) hydrochloride has been shown to reverse pulmonary resistance vascular remodeling, inhibit proliferation of pulmonary arterial smooth muscle cells (PASMCs) and airway smooth muscle cells (ASMCs), as well as protect PAECs from pathological stimulation.Iptakalim has an inhibitory effect on [Ca2+]cyt increase and the proliferation of pulmonary arterial SMCs induced by endothelin-1 through activation of KATP channels. Iptakalim (10 μM, 10 min) pretreatment of pulmonary arterial SMCs significantly prevents ransient ncrease of [Ca2+]cyt elicited by endothelin-1.Iptakalim at he concentrations of 0.1, 1, and 10 AM lowered[3H]thymidine incorporation by 19.75±4.60% (n=10), 41.20±9.49% (n=10), and 54.74±10.11% (n=10), respectively, compared with that of cells treated only with endothelin-1.
  • In Vivo
    Iptakalim (10-60 mg/kg) attenuates nicotine-evoked conditioned responding. Iptakalim also attenuates chamber activity in these nicotine test sessions..Iptakalim (60 mg/kg) pretreatment significantly reduced activity (LSD comparisons).. Animal Model:Thirty male Sprague-Dawley rats weighing 275-299 grams.Dosage:0, 10, 30, or 60 mg/kg.Administration:IP, 10 min before the start of a 4-min test session.Result:Decreased chamber activity.Dipper entries following pretreatment with 30 and 60 mg/kg Iptakalim were significantly lower than with 0 (saline) or 10 mg/kg iptakalim pretreatment (Tukey HSD tests).
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Aldose reductase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    642407-63-4
  • Formula Weight
    179.73
  • Molecular Formula
    C9H22ClN
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 25 mg/mL (139.10 mM)
  • SMILES
    Cl.CC(C)NC(C)(C)C(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Simard-Duquesne N, et al. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism. 1985 Oct;34(10):885-92.
molnova catalog
related products
  • AUT1

    AUT1 (AUT-1) is a novel specific modulator of Kv3 channels (EC50: 4.7 and 4.9 uM for Kv3.1b and Kv3.2a).

  • BL-1249

    BL-1249 is a selective and potent non-steroidal potassium channel activator with anti-inflammatory activity that activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2).

  • MonoMethyl auristati...

    Monomethyl auristatin F, an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin.